INKT

MiNK Therapeutics (INKT)

About MiNK Therapeutics (INKT)

MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded by Garo H. Armen in 2017 and is headquartered in New York, NY.

Details

Daily high

$11.50

Daily low

$10.95

Price at open

$11.10

52 Week High

$16.98

52 Week Low

$8.48

Market cap

56.1M

Dividend yield

Volume

6,787

Avg. volume

8,598

P/E ratio

-4.70

MiNK Therapeutics News